Published in:
01-09-2016 | Gastrointestinal Oncology
Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Published in: Annals of Surgical Oncology | Issue 9/2016
Login to get accessAbstract
Background
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is becoming accepted treatment for peritoneal carcinomatosis (PC) from colorectal cancer. Quality of life (QoL) for patients after surgery is still a concern amongst physicians despite studies that show that QoL recovers after surgery. We conducted a prospective QoL study on patients undergoing CRS and HIPEC and attempt to identify factors that affect the QoL.
Methods
Patients who underwent CRS and HIPEC for PC from colorectal cancer from March 2012 to January 2015 were included. The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30) and the colorectal module (QLQ-CR29) were administered prior to surgery and thereafter at 3, 6, and 12 months.
Results
Twenty-three patients underwent 25 procedures. Median disease-free survival was 12.9 months [95 % confidence interval (CI) 2.5–19.3]. Physical and role functioning scores decreased at 3 months but returned to baseline at 6 months. There were significant increases in emotional and social functioning scores at 6–12 months and improvements in all symptoms scales at 6–12 months, especially the fatigue and appetite scores. A higher PCI score, longer duration of surgery, the presence of a stoma, and recurrence within 3 months were associated with a poorer QoL.
Conclusions
QoL after CRS and HIPEC improved or returned to baseline in all categories by 6–12 months after surgery. Patient selection is important not only for improved survival but also for improved QoL.